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1. Introduction 
Cationic amphiphilic peptides (CAPs) are widely studied as effectors that are activated by 
microbial pathogens in immune signaling pathways of invertebrates and vertebrates. These 
peptides are non-specific effectors that can kill bacteria, fungi, viruses and protozoan 
parasites [1, 2]. They are a universal feature in all forms of life and are often found in all the 
major barriers such as the skin and epithelia that are naturally designed for protection 
against invading microorganisms. In the case of invertebrates, they play a pivotal role in 
innate immunity upon which these animals depend for defense against infection. The two 
immunes response strategies are interdependent and innate immunity has significant 
impact on the development of adaptive immunity [3-6]. In addition to innate immunity, 
vertebrates also rely on acquired immunity which is mediated by antibodies and cytotoxic T 
lymphocytes [7]. Identification of these antimicrobial peptides and the study of their 
structural  features have led to the development of peptide drugs, sometimes through the 
design of synthetic peptides based on the known structures of the natural ones. A subset of 
cationic peptides has been found to have anti-tumour as well as wound-healing properties 
extending the prospects of these peptides as templates for drug design strategies against 
cancer and wound treatment [8]. The mechanisms by which these latter properties are 
manifested are not fully understood.  Indeed, the mechanisms by which cationic peptides 
exert their wide biological activities are still under investigation and many theories have 
been proposed. 
The mode of action of cationic peptides appears to be reliant heavily but not entirely, on 
their structural and biophysical features. As their name suggests, they are characterized by a 
net positive change which contrasts conveniently with the negative charge that is 
characteristic of microbial membranes and cancer cells.  
Studies on the antibacterial peptide mode of action produced several models that suggest 
that the phospholipid bilayer forming membranes is the main target of peptide action. There 
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is, however, evidence that shows that some cationic peptides can cross the plasma 
membrane and interact with intracellular macromolecules.  
The mechanism by which cationic peptides inhibit viral infections is also not fully 
understood. They are understood to act primarily against enveloped RNA and DNA viruses 
but there are exceptions such as the non-enveloped adenovirus and a few others. Cationic 
peptides appear to target viral adsorption or the entry process, replication and gene 
expression [9] .  It remains to be seen if the mode of action against viruses can be correlated 
to secondary structure features of the cationic peptides. Current knowledge points to 
interactions with the extracellular matrix and with membrane or viral envelope proteins. 
Intracellular targets whereby the host is stimulated to act against the virus are also 
suggested. 
Antifungal peptides tend to be rich in polar and neutral amino acids suggesting a functional 
significance that is important for interfering with a unique fungal property. Furthermore, it 
has been shown that in peptides with activities against both fungi and bacteria different 
substitutions were required for optimizing the different types of activities. Overall, it seems 
that these peptides interact mainly with the phospholipid bilayer to effect lysis of certain 
microbes. However, mounting evidence that shows existence of intracellular targets that 
could be polypeptide or nucleic acid in nature, suggests a wider scope for investigation to 
establish how these peptides execute their biological functions. 
CAPs are attractive candidates for therapeutic use but their development for 
commercialization is hampered by certain crucial obstacles. In this chapter, biochemical 
interactions of CAPs together with prospects for commercialization are discussed. 
2. Classes of cationic peptides 
Broadly, there are two major classes of cationic peptides with antimicrobial activities (Table 
1). One group is produced by bacteria and fungi and consists of non-ribosomally 
synthesized peptides. These peptides are assembled by multifunctional peptide synthases in 
large and ordered multi-enzyme and co-factor systems following the “multiple carrier 
model” for peptide biosynthesis [10, 11]. Examples include Gramicidin, bacitracin, 
polymyxin B, streptogramins, vancomycin and others.   This biosynthetic process results in 
an extensive chemical variety that includes peptides containing hydroxyl- L- D- and 
unusual amino acids which can be further modified by methylation, acylation, glycosylation 
or cyclic ring formation [11]. The major disadvantage of these peptides is that bacteria 
develop resistance to them e.g.  vancomycin-resistant Staphylococcus aureus and enterococci 
[12, 13].  
The second major class includes gene-encoded ribosomally synthesized peptides which are 
further subdivided into bacteriocins (produced by bacteria) and antimicrobial peptides 
(produced by eukaryotes). The latter are the main object of this chapter. A prominent group 
of bacteriocins, composed of rare and modified amino acids is also called lantibiotics. A 
good example is nisin, a peptide produced by Lactococcus lactis with rare amino acids such  
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Non-ribosomally synthetized Gene-encoded
Contain a chemical variety of amino 
acid 
Mainly D-amino acids 
 Generally amphipathic with (12 – 20 amino acids) 
 Have a high net positive charge and hydrophobic 
residues 
Highly active at low concentrations Active at higher concentrations 
  
May be modified Carry no unusual posttranslational  modifications 
Narrow spectrum Broad spectrum 
Table 1. Comparison between gene-encoded and non-ribosomally synthetized antimicrobial peptides 
as lanthionine, 3-methyllanthionine, dehydroalanine and dehydrobutyrine [14]. Lantibiotics 
act by either pore formation leading to disruption of the bacterial cell wall or by interfering 
with biosynthesis of molecules such as the peptidoglycan component of the bacterial cell 
wall. This results in a thinner cell wall and eventual lysis of the bacterium [15].  
Antimicrobial peptides are divided into four major structural groups namely; (a) peptides 
that form α-helical structures, (b) cysteine-rich peptides with intramolecular disulfide 
bonds, (c) peptides that form β-sheets connected by a single or two disulfide bridges, and 
(d) peptides rich in particular amino acids such as histidine, glycine, arginine and proline or 
tryptophan [16-20] (Table2 and Figure 1).  They have considerable sequence diversity but 
share important physicochemical properties. They are 12 – 50 amino acids long, carry a 
positive (+2 to +9) charge and are composed of 40 – 50% hydrophobic residues. In their 
folded state, residues segregate into hydrophilic and hydrophobic clusters producing an 
amphipathic structure thus allowing them to be soluble in phospholipid membranes. The 
combination of these electrostatic and hydrophobic interactions results in membrane 
disruption and key structural features that contribute to their mode of action as described 
later in this chapter. 
It is worth noting that the antimicrobial activity of cationic peptides is dependent upon 
physiological conditions [1]. They are regarded as antimicrobial peptides if they can kill 
pathogens at physiological concentrations of divalent cations such as Mg2+ and Ca2+ (1-2 
mM), monovalent cations such as Na+ and K+ (100 mM) and polyanions and mucins. 
 
Peptide type Example References 
 α-helical structures, Cecropin A, magainins,dermaseptin, bombinin, 
mellitin, cathelicidin 
[16, 115, 
116] 
Rich in cysteine residues,   HNP-1, 2 and 3 (human defensins)  [117] 
β-sheets Tachyplesins  polyphemusin II (T22), lactoferricin [18-20] 
Rich in certain amino acids such 
as  histidine, glycine, arginine 
and proline or tryptophan 
Histatin (histidine), indolicidin (tryptophan), 
tritripticin, holotricin (glycine & histidine), coleoptericin 
(glycine), pyrrhocoricin (proline) 
[69, 118-
120] 
Table 2. Classes of AMPs 
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Figure 1. Structures and examples of cationic peptides representing different classes.. A. -helical 
peptide - BMA-27 (PDB ID: 2KET). B.-sheet peptide with disulfide bridges -  human defensin (PDB ID: 
3GNY) C. anti-parallel -sheet  -  tachyplesin 1 (PDB ID: 1WO1), D. peptides with amino acid bias -  
Indolicidin (PDB ID: 1G89). 
2. Modes of action of cationic peptides 
The activity of antimicrobial peptides (AMPs) and their potential use as therapeutic agents 
rely on differences between mammalian and bacterial subcellular structures as well as 
between normal and abnormal (apoptotic and tumour) mammalian cells.  The current 
dogma for microbial killing by cationic peptides is that they target the phospholipid bilayer 
and kill microorganisms by pore formation or membrane disruption leading to cell lysis. 
There is, however, growing evidence showing that some peptides act on intracellular 
macromolecular targets. In some cases it is debatable whether killing is due to intracellular 
targeting or a combination of this and membrane disruption. Nevertheless, good 
understanding of the mechanisms of action of AMPs should provide promising 
opportunities for drug design. Before reviewing their mode of action it is therefore 
necessary to consider the landscape of human and pathogen cell membranes. Generally, the 
cationic nature of antimicrobial peptides facilitates electrostatic attraction to the negatively 
charged microbial membrane phospholipids and their hydrophobicity facilitates cell 
membrane penetration. However, there are subtle differences in the mechanism of action of 
the various peptides. 
Structural features of animal and bacterial cells 
The distribution of phospholipids on the outer and inner leaflets of the plasma membrane in 
eukaryotic cells is asymmetric. Typically, the outer surface of normal mammalian cells is 
composed of neutral zwitterionic phospholipids and cholesterol [8]. It is largely composed 
of choline-containing phospholipids such as sphingolimyelin and phosphatidylcholine, 
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while aminophospholipids such as phosphatidyliserine and phosphatidylyethanolamine 
dominate the inner leaflet [21]. In addition to the heterogeneity of headgroups and acyl 
chains, the presence of cholesterol in animal cells introduces more complexity to the 
membrane landscape by promoting the formation of lipid microdomains [22].  
On the other hand, bacterial membranes are predominantly composed of acidic 
phospholipids (such as phosphatidylglycerol and cardiolipin) that confer a net negative 
charge to the surface of the membrane while phosphatidylethanolamine and 
phosphatidylserine are not detectable [23-25]. Since AMPs have to cross the negatively 
charged lipopolysaccharide layer before reaching the membrane, the possible impact of this 
barrier has been investigated. The negative charge on the lipopolysaccharide (LPS) rather 
than the size of the saccharide moiety is important for susceptibility of the bacterial cell to 
antimicrobial activity of the cationic peptides. This was demonstrated by experiments using 
bacterial LPS mutants with varying lengths of the polysaccharide moiety but an equal 
number of phosphate groups. In these mutants the phosphate groups would, however, be 
heterogeneous due to further modifications resulting in diverse phosphorylation patterns 
amongst mutants. It was found that the LPS mutants display differential susceptibility to 
cationic peptides in a manner that seems to be related to charge location and magnitude and 
to absence or presence of the O-antigen side chain [23, 26]. It is proposed that because of 
their greater affinity for LPS than divalent cations and their bulkiness, cationic peptides 
competitively displace these ions and create a passage through the outer bacterial 
membrane thus propelling themselves to the cytoplasmic membrane by a “self-promoted 
uptake” [27].  
Loss of asymmetry with distinct bias in phospholipid types is observed in tumorigenic cells 
when compared to animal cells. Cancer cells are known to carry a predominantly negative 
charge due to high levels of the anionic phosphatidylserine, O-glycosylated mucins, 
sialylated gangliosides and heparin sulphates [28, 29]. The membranes of tumorigenic cells 
also contain a significantly higher number of microvilli compared to normal cells effectively 
increasing the surface area of cancer cells [21].  
Cationic peptides interactions with the phospholipid bilayer of membranes 
Cationic peptides are attracted to the negatively charged prokaryotic membranes and kill 
microbial pathogens by causing disintegration of their membranes and subsequent collapse 
of electrochemical gradients  [23, 30, 31]. Various models of membranolytic activities of 
AMPs have been proposed. These include the (i) barrel stave   (ii) Carpet (iii) toroidal model, 
and (iii) channel-forming models reviewed in [2, 32, 33] .  
i. The barrel stave model – this model is based on the amphipathic -helical peptides 
forming contacts with headgroups on the inner and outer surfaces of the membrane 
bilayer using their hydrophilic ends while their hydrophobic regions make contact with 
the acyl chains of the phospholipids. This results in transmembrane pore channels 
whose inner surface or lumen consists of the hydrophilic regions of the peptides. 
Binding to the membrane is probably driven by hydrophobic interactions with the 
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membrane hydrophobic core and requires aggregation of several peptide monomers or 
oligomers in an -helical form. This model proposes a stepwise sequence beginning 
with the peptides reaching the membrane and assembling at the surface. After 
recruitment of more monomers, they   insert into the core of the membrane. Only a few 
pores are required to dissipate the transmembrane potential in cells [34]. The ”barrel 
stave” model applies to certain peptides such as the non-ribosomally synthesized 
antibiotic, alamethicin [35] and the gene-encoded pardaxin, a polypetide Purdachirus 
marmorutus toxin with a helix-hinge-helix structure [36, 37]. 
ii. The carpet model – was first described for the action of dermaseptin and later for 
cecropin, the human cathelicidin LL-37 and others [33]. Binding of these peptides to the 
membrane is initially electrostatically driven and the peptides are not required to adopt 
a particular structural form. It is proposed that binding to bacterial membranes takes 
place in four defined steps [33, 34]. Initially, the peptides make contact with the LPS on 
Gram-negative bacteria or the teichoic acids on Gram-positive bacteria and traverse the 
membrane in a carpet-like fashion. The peptides then align themselves such that their 
hydrophobic regions face the lipids and their hydrophilic regions face the phospholipid 
headgroups. This is followed by the accumulation of peptides until a threshold 
concentration is reached. Finally, the peptides permeate the membrane and disrupt it 
causing the collapse of the bilayer. This model is sometimes referred as the detergent 
model and is characterized by the accumulation of the peptide which drives the eventual 
catastrophic collapse of the membrane. 
iii. The toroidal model – was first proposed by [38, 39] to describe the action of the Xenopus 
laevis AMP, magainin 2. Later it was found that peptides such as mellitin and protegrins 
also induce transmembrane pores in the toroidal fashion [35]. In this model, the 
peptides aggregate such that both the phospholipid headgroups of the monolayers and 
the peptides line the lumen of the pore. This results in the formation of a dynamic core 
consisting of the lipid monolayers and peptides with a characteristic lipid flip-flop. 
iv. The aggregate or channel-forming model – appears to be a subtle variation of the toroidal 
mechanism. It was first suggested after a study using short (10 – 14 amino acids) 
peptides and a membrane potential-sensitive cyanide dye. This model portrayed 
concentration- and voltage dependent peptide aggregation within the membrane 
without any fixed stoichiometry [40]. It was also described for sapecin, an antibacterial 
insect defensin isolated from the flesh fly, Sarcophaga peregrina [41]. In this study, the 
initial attraction to the membrane was found to be electrostatic with cardiolipin playing 
an important role. It had been shown previously that sapecin has a remarkable affinity 
for cardiolipin which is abundant in Staphylococcus aureus. Furthermore, E. coli mutants 
defective in cardiolipin synthesis were resistant to sapecin compared to wild type E. coli 
[42]. Using glucose leakage experiments it was shown that membrane permeabilization 
is dose-dependent and follows a sigmoidal curve.  This cooperativity suggests that 
oligomerization is an important factor during permebilization [41]. A similar 
mechanism was noted in a previous study involving the wasp venom mastoparan 
which was found to exhibit pore formation dynamics that are concurrent with mellitin 
but with some differences [43, 44].  
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A recent review of these peptide modes of action introduces new models that have been 
proposed. Some of these are variations of the older ones described above [45]. They include 
the detergent model, the sinking raft model, the lipid clustering mode, the interfacial activity models 
and molecular shape model. These models have the common premise of non-pore formation.  
Cationic peptide interaction with nucleic acids 
There is considerable evidence that shows that some antimicrobial cationic peptides can 
pass the membrane with minimum disruption, suggesting that they may have intracellular 
targets. Furthermore several peptides have been shown to bind DNA in vitro. Others inhibit 
important cytosolic proteins thereby interfering with key cellular processes.  
When, tachyplesin, a 17 residue arginine-rich peptide, was isolated it was shown to kill 
bacteria at low concentrations and to form complexes with bacterial lipopolysaccharide [46]. 
While evidence indicates that tachyplesin interacts with lipid membranes and kills bacteria 
by leakage, the exact mechanism of leakage and killing remains poorly defined [47]. 
Tachyplesin I is a cyclic broad-spectrum antimicrobial peptide with a rigid, antiparallel β-
sheet and two intramolecular S-S linkages [46]. This structural motif is known to contribute 
to DNA binding [48].  Indeed, using DNase1 protection and other  DNA footprinting-like 
techniques [49] showed that tachyplesin binds DNA. Furthermore, they showed that it 
probably binds to the minor groove as methylation of a guanine in the major groove was not 
affected by the presence of the peptide. However, the antiparallel -sheet motif has been 
shown, by 3D solution structures of DNA complexes with proteins, to be involved in DNA 
binding by making contacts with the major groove [50, 51]. The chemical configuration in 
the major and minor groove is important as it indicates specificity and non-specificity or 
interactions respectively.  
Another member of the tachyplesin family, polyphemusin I also accumulates in the 
cytoplasm fairly rapidly without causing membrane damage and shows subtle signs that it 
may interact with DNA [52].  In crossing the plasma membrane these peptides induce 
transient pore formation and membrane permeability [53-55]. Using unmodified and 
PEGylated versions tachyplesin I was shown to induce lipid flip-flops characteristic of the 
toroidal mode of pore formation. In these experiments, PEGylation did not alter the mode of 
interaction between the peptide and lipid membranes but lowered both DNA binding 
ability and antimicrobial activity.  It may be reasonable therefore to assume that tachyplesin 
targets both the membrane and DNA but the main method of bacterial killing is still elusive.  
Buforins represent another group of AMPs that translocate across the membrane via 
transient pores. The 21 amino acid peptide buforin 2 is a more potent derivative of buforin 1 
and has broad spectrum antimicrobial activity [56]. It is translocated across the lipid bilayer 
in a manner similar to maganin2 but without inducing severe membrane permeabilization 
due to a proline (Pro11) that distorts the helical form of the peptide, concentrating basic 
amino acids in a limited amphipathic region and thereby enhancing electrostatic repulsion 
within and efficient translocation through the pore. The rapid and transient nature of the 
translocation limits membrane permeabilization by buforin 2. DNA–binding studies show 
that buforin 2 binds DNA and RNA and that buforin influences cellular processes to do with 
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nucleic acid metabolism [56, 57]. Buforin IIb, an anticancer synthetic analogue of buforin II, 
crosses the membrane without causing damage and accumulates in the nucleus. 
Furthermore, buforin IIb accumulates primarily in nuclei of Jurkat cells and induces 
mitochondria-dependent apoptosis in a mechanism that is not clearly understood [58]. 
Buforin 1 and II share complete sequence identity with the N-terminal region of histone 
H2A (H2A tail)  that interacts directly with nucleic acids [59]. The H2A tails   play a crucial 
role in maintaining the stability of the nucleosome by making specific interactions with 
DNA. In the nucleosome particle, they adopt a disordered conformation with many residues 
not making contact with DNA. The arginines, however, interact with the minor groove [60]. 
It is not clear whether the H2A tail interaction with chromatin can be taken as a model for 
buforin interactions. The helix–hinge-helix structure of buforin has been evaluated using 
phospholipid interactions but interactions with DNA have so far been demonstrated using 
techniques such as electrophoretic mobility shift assays. A 3D solution structure of a 
buforin- DNA complex may elucidate the exact nature of their interaction. 
The actual contact between an AMP and DNA was demonstrated with indolicidin, a potent 
cationic peptide that enters bacterial cells without causing lysis and inhibits DNA 
replication [61]. These experiments showed that indolicidin assumes different environment-
dependent conformations and prefers to bind certain sequences of double stranded DNA 
and that it binds poorly to single stranded DNA . This provides evidence that peptide-DNA 
interactions are not simple electrostatic attractions.  Specific DNA-peptide interactions are 
often facilitated by the major groove environment which has richer chemical information 
than the minor groove [62, 63].  It may be expected then that the peptide makes specific 
contacts such as hydrogen bonds and hydrophobic interactions in the major groove and 
electrostatic contacts with the phosphate backbone.  Other peptides may interact with 
nucleic acids.  .  
The DNA-binding property of cationic peptides together with subcellular localization into 
the nucleus may provide opportunities for development of delivery systems. Indeed a 
cationic amphipathic peptide called KALA was designed  for delivery of DNA into cells 
[64].  Similarly the histidine-rich synthetic peptide known as LAH4 was also developed as a 
DNA carrier that can be used in a wide variety of applications including basic research, 
therapy and vaccination [65]. These prospects underline the importance of investigating the 
precise nature of the interaction between cationic peptides and nucleic acids. 
Cationic peptide interaction with other subcellular targets 
As stated earlier, some antimicrobial peptides have the ability to transiently permeabilize 
and translocate across the plasma membrane and cause death of the target pathogen 
without causing cell lysis. This indicates that these peptides may have intracellular targets. 
It is recorded that such cellular targets could include macromolecules in protein and lipid 
biosynthetic pathways and in nucleic acid metabolism (Table 3 and 4). It has not been 
established whether there are unique characteristics possessed by this class of peptides 
enabling them to target intracellular molecules.   
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Peptides Mode of action Reference
Buforin II and buforin IIb Binds DNA [56, 58, 70] 
Tachyplesin Binds DNA [48, 121] 
Mersadin Inhibits cell wall synthesis [122] 
PR-39 Inhibits replication and protein synthesis  [123] 
PR-26 Alters cytoplasmic membrane  [124] 
Indolicidin Replication, Alters cytoplasmic membrane [61, 125] 
Microcin 25 Alters cytoplasmic membrane  [126] 
Pleurocidin Inhibits nucleic acid metabolism [127] 
HNP-1 Inhibits nucleic acid metabolism [128] 
HNP-2 Inhibits nucleic acid metabolism [128] 
Dermaseptin Inhibits nucleic acid metabolism [127] 
Histatins Inhibits enzyme activity [129] 
Pyrrhocoricin Inhibits enzyme activity  [129] 
Drosocin Inhibits enzyme activity  [129] 
apidaecin Inhibits enzyme activity  [129] 
Pre-elafin/trappin-2 Binds DNA [130, 131] 
Lactoferricin  Regulation of transcription [54] and references therein 
Cecropin A Gene expression [132] 
Table 3. Cationic peptides with intracellular killing activities 
 
AMP Interacting molecule Reference 
PR-39  Membrane receptor, multiple, SH3 domain-containing 
intracellular proteins and p85a (regulatory subunit of 
phosphatidylyinositol 3-kinase, (nucleic acids unconfirmed) 
[123, 133] 
Buforin II Nucleic acids (both RNA and DNA), inhibits transcription or 
translation 
[56] 
Mellitin  Hyperactivation of phospholipase A2  
Tachyplesin C1q activating the classi complement pathway [91] 
Lactoferricin B Heparin-like molecules preventing angiogenesis [96] 
Histatin 5 67 kDa fungal protein [74] 
Histatin 5 B. gingivalis trypsin-like protease [78] 
Pyrrhochoricin, drosocin, 
apidaecin 
DnaK preventing chaperone-assisted protein folding [66, 67] 
Apidaecins Probably a permease transporter and protein involved in 
protein synthesis 
[85] 
Cathelicidin LL-37/ hCAP-
18 
binds to formyl peptide receptor-like 1 
(FPRL1), a G protein-coupled, seven-transmembrane cell 
receptor found on various cell types including 
macrophages, neutrophils and subsets of lymphocytes 
[100] 
Mouse Cathelin-related 
antimicrobial peptide 
(CRAMP) 
binds to formyl peptide receptor-like 1 
(FPRL1) 
[101] 
Table 4. Putative non-lipid molecular targets of CAPs   
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Peptides that belong to the proline-rich family, pyrrhocoricin, apidaecin and drosocin enter 
bacterial cells and macrophages and are distributed in all cellular compartments.  These 
peptides bind specifically to the E. coli 70 kDa heat shock protein, DnaK preventing 
chaperone-assisted protein folding and death of the bacterium [66]. They appear to enter the 
cell in a LPS-mediated manner. Importantly, they do  not bind to the equivalent human 
Hsp70 protein,  pointing to a potential pharmaceutical benefit [67].  
Proline is known to be a unique amino acid in facilitating macromolecular binding. Due to 
some unique biophysical reasons proline was found to facilitate macromolecular 
interactions by means of proline-rich motifs or even as a single proline residue [68]. Indeed 
it has been suggested that proline-rich modules may be a natural occurrence that facilitates 
membrane penetration [69]. Several examples have been recorded indicating that proline is 
important in AMP activity. The DNA-binding buforin II has a proline hinge which is crucial 
for membrane penetration [59, 70]. Cathelicidins have a -helical N-terminus with 
antibacterial activity and a proline-containing C-terminus that is required for membrane 
penetration [69].  The endogenous proline-arginine (PR)-rich peptide, PR-39 inhibits NDPH 
oxidase by docking to the Src homology 3 (SH3) domain of this enzyme [71].  PR-39 is also 
implicated in blocking DNA replication [72]. This is consistent with established observations 
that proline-rich motifs are crucial for bind to signaling molecules with domains such as 
SH3 [68]. Detailed Structure-based analysis of the proline-rich motif and SH3 domain 
interaction shows how a crucial RXL motif in proline-rich ligands binds to the SH3   domain 
[73].  Systematic mutations of residues in the SH3 domain and the proline-rich ligand 
revealed that two crucial prolines interact directly with the domain while others form a 
molecular scaffold. Furthermore, arginine and lysine residues are involved in extensive 
interactions conferring specificity.   
Some AMPs that are likely to have intracellular targets use unconventional mechanisms to 
enter the cell. These include the histatin family and apidaecins. Histatins, a family of 
histidine-rich AMPs found in human saliva enter the cell in a receptor-mediated manner 
and target the mitochondria [74]. The histatin family consists of AMPs that have potent 
activity against fungi and constitutes an important aspect of antifungal and wound healing 
activity in the oral cavity [74, 75]. It was found that histatin 5 kills intact Candida albicans  
without causing lysis and that spheroplasts (fragile with fragments of the cell wall)  were 14-
fold less susceptible compared to the intact cells. Binding studies showed that histatin 5   
targets at least one specific protein that was detected in whole cell extracts and crude 
membrane fractions but not in the cell wall fraction and in spheroplasts [76].  Surprisingly, 
the human neutrophil defensin 1 (HNP-1) which differs structurally to histatins appeared to 
act in the same manner as histatin 5, probably sharing the same molecular target in Candida 
albicans [77]. Besides, histatin 5 was found to be an inhibitor of B. gingivalis trypsin-like 
protease probably accounting for natural protection against periodontitis [78]. They reduce 
the activity of a Bacteroides gingivalis trypsin-like protease by competitive inhibition [78]. 
This protease may be responsible for the periodontitis caused by B. gingivalis [79, 80], 
implying that histatins play an important role in combating oral pathogens. This was 
initially observed with lantibiotics such as nisin Z which uses Lipid II as a receptor [81] and 
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mesentericin Y,  a 37 amino acid peptide isolated from Leuconostoc mesenteroides. This 
peptide targets a specific receptor found only on the food-borne listeria. Generally, these 
peptides a have a characteristic structure with two domains; a recognition domain for 
binding to a receptor and an -helical domain responsible for pore formation. Removal of 
the recognition domain results in loss of pathogen selectivity. 
Some peptides exhibit anti-viral activity by mechanisms that albeit poorly understood, 
appear to be non-membrane dependent. The synthetic [Tyr5,12,Lys7]-polyphemusin II 
peptide (T22) inhibits HIV replication apparently by competition with cellular proteins 
required for viral attachment e.g. CD4 [82]. Mellitin and its inactive analogue can 
competitively inhibit the infectivity of the tobacco mosaic virus due to structural similarities 
with the virus capsid region required for RNA interaction [83].  
Apidaecins are short proline-arginine-rich and highly antibacterial peptides that kill Gram-
negative bacteria without forming pores [84, 85]. Their activity is limited to Gram-negative 
bacteria. Interestingly, they are distant relatives of the mammalian peptide PR-39. Apidaecin 
uptake was found to be actively driven by an energy-dependent mechanism, stereospecific 
and irreversible.  The transporter-mediated model was demonstrated by the fact that 
pretreatment of cells with an oxidative phosphorylation uncoupler reduced uptake of 
apidaecin but did not prevent the uptake of a known pore-former, D-Mag (all D-magainin 
isomer).   Furthermore, uptake of the apidaecin peptide was reduced by the presence of a 
proline-rich peptide (L-Pro) but not its enantiomer (D-Pro) indicating receptor dependence. 
Apidaecin may also act downstream on at least one indispensable cellular target as some 
peptide analogs entered the cell without killing it. Inhibition of protein synthesis by 
apidaecin suggests that it interferes with the translation machinery of the bacterium. The 
probable target is the 30S ribosomal subunit as cooperative inhibition by tetracycline (a 
known inhibitor of this subunit) and apidaecin was demonstrated [85]. Apidaecin is also 
implicated in interfering with protein folding by inhibiting the activity of DnaK [67, 86]. 
Since apidaecins are non-toxic to human cells better understanding of their mode of action is 
necessary. It seems probable that the intracellular targets of apidaecin are unique to Gram-
negative bacteria. Nevertheless, the identification of intracellular targets of AMPs in general 
is important for the design of species- or strain-specific drugs.  
Role of cationic peptides in anticancer therapy and wound healing 
Current anticancer agents have limited success due to non-selective killing of cancer and 
normal cells and often result in the development of resistance. The discovery of new 
anticancer strategies is therefore urgent. Many studies have shown that cationic AMPs have 
anticancer properties. These peptides are divided into two classes; one that consists of 
peptides that are toxic to bacteria and cancer cells but not to human cells and another class 
with peptides that are toxic bacteria and to both cancer and normal human cells [87]. It is 
believed that they have membranolytic and non-membranolytic modes of action [8, 28]. The 
membranolytic activity is presumed to be based on the different compositions of cancer and 
normal membranes and includes the disruption of mitochondrial membrane.  The 
disruption of the membrane probably occurs by some of the modes describes earlier; such as 
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the “carpet” model.  These peptides can also cause permeation of the mitochondrial 
membrane releasing cytochrome c followed by apoptosis. Such apoptosis would also cause 
caspase 9 activation and conversion of pro-caspase3 to caspase 3. Buforin IIb which 
displayed selective cytotoxicity against 62 cell lines provides a good example in this 
instance. It crosses cell membranes without causing damage and causes mitochondria-
dependent apoptosis characterized by caspase 9 activation [58]. The exact mechanism of 
apoptotic killing is not clear as it is for many other cationic peptides. Mitochondria-
dependent apoptosis can also occur by the death receptor associated pathway [88].   
It seems that different Amps induce different apoptotic pathways and membranolytic 
mechanisms. A COOH-terminal fragment of the cathelicidin LL-37 pre-protein, hCAP-18 
was found to selectively kill oral squamous carcinoma cells and not healthy human 
fibroblast or HaCaT cells by apoptosis that is characterized by mitochondrial depolarisation 
with no detectable caspase 3 or in a caspase-independent mechanism  [89]. Tachyplesin that 
was conjugated to an integrin homing peptide killed both tumour and endothelial cells by a 
mitochondrial and death receptor -dependent pathways [90]. On the other hand, tachyplesin 
was shown to kill tumour cells by interacting with hyaluronan and C1q a key component of 
the complement pathway thus activating the classic complement pathway leading to loss of 
membrane integrity and cell lysis [91].  
The non-membranolytic mechanism is probably facilitated by interaction with specific 
proteins or through processes that activate specific intracellular molecules.  Mellitin is 
reported to selectively promote the destruction of ras oncogene-transformed cells by 
preferentially activating phospholipase A2 and causing calcium influx [92, 93]. Lactoferricin 
B (LfcinB), a cationic AMP that is cytotoxic to human and rodent cancer cells, kills human 
leukaemia and breast carcinoma cells by a sequential process involving generation of 
reactive oxygen species, mitochondrial membrane depolarization and activation of the 
caspase cascade leading to death by apoptosis [94]. However, LfcinB kills human B-
lymphoma cells in a caspase-independent mechanism [95]. Furthermore, LfcinB was found 
to prevent angiogenesis by interacting with a heparin-like molecule on the surface of human 
umbilical vein endothelial cells (HUVECs) [96].  
There is a growing number of AMPs that appear to promote wound healing. It is generally 
noticeable that wounds in the oral cavity heal faster than skin lesions for example but it has 
emerged recently that this may be attributable to the histatin family, at least in part. At least 
two histatins have been identified as the major wound healing factors in human saliva [75]. 
Moreover this property was associated with active uptake of histatin by epithelial cells and 
the activation of an extracellular signal-regulated kinases ½ signalling pathway suggesting a 
mechanism by which these peptides effect their non-AMP role. Wound healing is a localized 
process which involves inflammation, wound cell migration and mitosis, neovascularization, 
and regeneration of the extracellular matrix and is known to be mediated by peptide growth 
factors such as the epidermal growth factor (EGF) and transforming growth factor alpha 
(TGF-α) [97]. At least TGF- has been shown to act by activating the expression of AMPs 
hCAP-18/LL-37 and human -defensin 3 in addition to the larger proteins often found during 
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injury,  the neutrophil gelatinase-associated lipocalin, and secretory leukocyte protease 
inhibitor in human keratinocytes [98]. And cathelicidins are known to regulate cellular 
responses including cell proliferation, cell migration of inflammatory cells, release of 
cytokines and angiogenesis [99]. The cathelicidin hCAP-18 interacts with formyl peptide 
receptor-like 1 (FPRL1), a G protein-coupled, seven transmembrane cell receptor [100]. And 
the only known mouse cathelicidin-like protein the cathelin-related antimicrobial peptide 
(CRAMP) known to be angiogenic was further shown to be chemotactic for human 
monocytes, neutrophils, macrophages, and mouse peripheral blood leukocytes [101]. Clearly, 
as the multi-functional role of antimicrobial peptides unravels, the number of peptides 
involved in non-infection related processes and new molecular targets are set to increase. 
3. Drug design strategies 
Cationic antimicrobial peptides have key characteristics that make them attractive 
candidates for pharmaceutical development: (i) they are active against a broad spectrum of 
Gram-negative and Gram-positive bacteria (including the multiple drug resistant strains), 
fungi, viruses and protozoa – a single peptide can act against all these pathogens (ii) 
generally, they do not target specific pathogen molecules reducing development of 
resistance, and (iii) they are potent and kill pathogens rapidly [1, 102]. There are, however, 
obstacles that hinder the commercialization of AMPs. Commercialization of antimicrobial 
peptides is hindered by various pharmacokinetic obstacles that may require some 
engineering to resolve and are indeed the object of intensive research worldwide. 
Absorption, distribution, metabolism and excretion (ADME) are vital pharmacokinetic 
parameters that must be satisfied by successful drug candidates, and major challenges have 
emerged with respect to peptide drugs. Some of the key shortcomings that should be 
addressed to improve rational peptide-based drug design are: 
i. Low bioavailability  
ii. Toxicity  
iii. High cost of production 
There are several ideas about to overcome some of them (Table 5) and many researchers are 
investigating ways to remove these obstacles and move to commercialization. 
Bioavailability and biodistribution 
Peptide drugs have to overcome barriers that affect absorption, transport (systemic 
distribution) and translocation through membranes. These barriers are associated with the 
physicochemical properties of peptides such as aqueous solubility, lipophilicity, hydrogen 
bond formation and metabolic stability.  Rapid degradation by proteolytic enzymes of the 
digestive tract, blood plasma and tissues is one of the major limitations attributed to peptide 
drugs as it limits oral availability and injection. These scenarios are further complicated by 
the fact that peptides are also subjected to rapid clearance by the liver and kidneys. Their 
physicochemical properties such as hydrophilicity and high conformation flexibility (no 
selectivity by specific receptors) also affect biodistribution.  
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Limitation  Cause Solution Reference 
High cost Regulatory and technological 
factors 
Development of efficient 
and robust process of 
chemical synthesis  
Design short and 
compositionally simple 
peptides 
 
[114, 134] 
Low (especially 
oral) bioavailability
Peptides being substrates of 
digestive enzymes, blood 
plasma and tissues 
Rapid hepatic clearance 
Rapid renal clearance 
Poor biodistribution 
Use of D-amino acids 
Peptide backbone 
alterations 
Protective delivery systems 
Chemical modification of 
protease cleavage sites 
[1, 135] 
Poor 
biodistribution 
Hydrophilicity  
High conformational flexibility 
– non selective 
  
Toxicity Immunogenicity 
Non-specific targets 
Some act on growth factors 
(wound healing) – may 
promote tumourigenesis 
Pro-drug use e.g mellitin-
biotin conjugates 
[111] 
 
 
 
 
Table 5. Challenges in drug design  
There are several approaches to optimize lead peptides to circumvent bioavailability and 
biodistribution obstacles. These include (i)  replacement of natural with unnatural or D- 
(rather than L-) amino acids, (ii) use of peptidometrics introducing non-peptidic backbones, 
(iii) adopting alternative formulations such as liposomes and (iv) modification to create 
protease resistant prodrugs [103]. The routes of drugs given systemically and orally are 
shown schematically in Figure 2 and Box 1 to indicate pharmacokinetic obstacles.  
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Figure 2. Distribution of drugs given intravenously and orally and obstacles that affect bioavailability. 
To be read together with Box 1. 
 
BOX 1 
When a drug is given intravenously it enters the systemic circulation via the right ventricle 
of the heart , flows past the lungs, into the left ventricle and finally into the rest of the 
circulatory system (Figure 2). Oral administration introduces the peptide into the strongly 
acidic environment of the stomach and later to high levels of proteolytic enzymes in the 
intestines. The main limitations to bioavailability of antimicrobial peptides are pre-
systemic and systemic enzymatic degradation. When the peptide is given orally it could 
also undergo “first-pass” metabolism in the liver and the gastrointestinal tract. The major 
threat to the peptides lies in the small intestine where there are large quantities of 
peptidases [136]. Oral and intravenous delivery of peptides is therefore a major challenge 
for pharmaceutical science and demands innovative strategies. Biological barriers such as 
the Blood Brain Barrier (BBBB) and placenta are additional obstacles to delivery of AMPs. 
Strategies that can be considered to circumvent these problems are: 
i. Alternative routes of administration 
- Subcutaneous injection 
- Intramuscular 
- Mucosal (nasal sprays) 
- Sublingual delivery  
- Transdermal routes (patches) 
ii. Penetration enhancers 
iii. Protease inhibitors 
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Toxicity 
Broadly, antimicrobial peptides are able to disrupt prokaryotic but not eukaryotic 
membranes because the latter are composed of zwitterionic phospholipids and contain 
cholesterol. Consequently, they appear to be non-toxic to animals. However, some peptides 
have been shown to translocate into cells and even carry other molecules with them. Indeed 
some cationic peptides are proposed as carriers for macromolecules such as DNA in certain 
instances [104, 105]. Due to incomplete knowledge about the action of AMPs on the 
eukaryotic cell, toxic effects of their application cannot be ignored or taken lightly. Indeed, 
all the commercially available AMPs are for topical applications and there is lack of 
confidence in other forms of administration. 
About 38% of drug candidates are abandoned in Phase I clinical trials because of toxicity 
[106]. However, many cationic antimicrobial peptides appear to have no cytotoxicity against 
mammalian and are therefore considered good candidates for treating infections. One 
example is plecstasin,  a defensin with a derivative known as NZ2114 and shown to have  
additional physicochemical benefits that allow it to cross the blood brain barrier making it 
attractive for treating meningitis [107]. Furthermore plecstasin can be used at high doses 
without toxicity to animal cells [108]. Apidaecins constitute another group of apparently 
non-toxic candidates and have been discussed earlier in the chapter. Toxicity, of 
antimicrobial peptides is still a matter not rigorously investigated to date. Often their 
hemolytic activity is tested.  
There are many unresolved issues about the mechanism of killing of AMPs compounded by 
the probable existence of intracellular targets. Fears are caused by the possibility that 
toxicity could emerge in vivo based on interaction between the AMPs and unknown 
subcellular targets. Currently, there is accumulating evidence showing that AMPs can kill 
eukaryotic cells by apoptosis. Two cathelicidins, BMAP-27 and BMAP-28 were shown to be 
toxic to transformed cell lines, fresh tumor cells and proliferating lymphocytes at 
microbicide concentrations. This cytotoxicity is associated with membrane disruption, 
calcium influx and subsequent apoptosis [109].  AMPs are apparently attracted to these cells 
because of an increase in negative charge introduced by sialylation of glycoproteins on 
transformed cells and activated lymphocytes as treatment of U937 cell by neuraminidase 
abrogated the toxic effect.  Furthermore, the human cathelicidin LL-37 was shown to induce 
apoptosis in vitro in a human airway epithelial cell line and in vivo in a murine airway [110]. 
LL-37 induced dose-dependent and caspase 3 dependent apoptosis in human lung epithelial 
cell line A549 [110]. This cell death was inhibited by caspase 3 inhibitor and by human but 
not by bovine serum. Clearly, there is need to investigate the physiological impact of AMPs. 
Toxicity can be addressed by several means including the use of prodrug format whereby a 
drug conjugate is designed to be activated at specific tissues. For instance, the anticancer 
peptide mellitin was conjugated to a biotin moiety which could be selectively cleaved in 
ovarian carcinoma cells by matrix metalloproteinase-2 which are highly expressed in these 
cells [111]. 
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Cost of production 
Cost of peptide production tended to increase at an alarming rate in the past decade due to 
regulatory and technological factors [112].  Technically, the cost of producing a peptide is 
dependent on size. Size also determines the method of production. Peptides may be 
produced by chemical synthesis, recombinant DNA technology, cell free expression 
systems, enzymatic synthesis and by the use of transgenic animals and plants. Since these 
peptides can sometimes involve unnatural amino acids, chemical synthesis may provide a 
wide range of peptide derivatives. To this end the discovery of the solid phase peptide 
synthesis method was a major step boosting peptide drug production [113]. It is now 
possible to produce peptides as long as 50 amino acids by chemical synthesis and produce 
therapeutic peptides on a large scale [114]. Indeed, now the chemical synthesis of peptides 
provides cheaper manufacturing costs compared to recombinant production [103]. This 
obstacle is likely to be overcome in the near future. 
4. Conclusion 
Cationic peptides are attractive molecules for clinical use. They have multifunctional 
properties as anti-infective agents that are able to kill bacteria, fungi, viruses and parasites 
as well as cancer cells. Their activity depends largely on their structural features and unique 
features in the landscape of prokaryotic and eukaryotic cell membranes. Some of these 
peptides have gone through clinical trials and reached commercialization but only for 
topical application. There are many obstacles that hinder development of cationic peptides 
for administration by the oral route or by injection. These are bioavailability, biodistribution 
and potential toxicity. These obstacles can be overcome by better understanding of the 
mechanism of action and killing of these peptides. More research is required in this area. 
The high cost of production has been a major obstacle for a long time. New advances in the 
chemical synthesis technology have greatly reduced the cost of production and now large 
scale chemical synthesis is possible. This method is preferable because of the opportunities it 
provides for the inclusion of unnatural amino acids during production. Recombinant DNA 
synthesis is another method that can be perfected to manufacture peptides at low cost. 
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